Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10679170 | 1.00 | BTN3A1 (0.32) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL3616995 | 1.00 | BTN3A1 (0.32) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL4217873 | 0.86 | NOS1 (0.33) | BTN3A1 | |
| SCHEMBL30980082 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL19699429 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL1067509 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL1067514 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL20591675 | 0.81 | NOS3 (0.38) | KIF11 | |
| SCHEMBL21224417 | 0.81 | — | — | |
| SCHEMBL21224419 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312349-B2 | Apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| EP-4119560-B1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-06-05 | — | — | EP | disclosed |
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116589459-A | Apoptosis inducer | 重庆复创医药研究有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-110546151-B | Apoptosis inducer | 重庆复创医药研究有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4119560-A1 | APOPTOSIS-INDUCING AGENTS | Shanghai Fochon Pharmaceutical Co., Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| CN-1938301-A | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors | TANABE SEIYAKU CO (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
| EP-1732924-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| EP-1400515-A1 | CYCLIC DIAMINE COMPOUND HAVING FIVE-MEMBERED CYCLIC GROUP | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-0900211-B1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | UPJOHN CO (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6472386-B1 | Cyclic diamine compound with 5-membered ring groups | KOWA CO., LTD. (JP) | 2002-10-29 | — | — | US | disclosed |
| US-5847148-A | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-4751299-A | Optically active β-lactams and method of their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0144840-A2 | Optically active beta-lactams and method of their production | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312349-B2 | Apoptosis-inducing agents | BCL2, BAX, BAD | BTN3A1 3476/4885KIF11 4485/4885CA1 2744/4885 |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | BTN3A1 3530/4885KIF11 4287/4885CA1 4295/4885 |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | BTN3A1 3958/4885KIF11 2027/4885CA1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.